# Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)

> **NCT00894075** · PHASE2 · WITHDRAWN · sponsor: **Alexion Pharmaceuticals, Inc.**

## Conditions studied

- Hypophosphatasia

## Interventions

- **BIOLOGICAL:** ENB-0040

## Key facts

- **NCT ID:** NCT00894075
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-07
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn pending further review of clinical design.
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00894075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00894075, "Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00894075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*